OMICS and brain tumour biomarkers

References

• Murphy M, Loosemore A, Ferrer I, Wesseling P, Wilkins P R, Bell B A. Neuropathological diagnostic accuracy. Br J Neurosurg 2002; 16(5)461–464
   PubMed Web of Science ®Google Scholar
• Field M, Witham T F, Flickinger J C, Kondziolka D, Lunsford L D. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 2001; 94(4)545–551
   PubMedGoogle Scholar
• Regis J, Bouillot P, Rouby-Volot F, Figarella-Branger D, Dufour H, Peragut J C. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. Neurosurgery 1996; 39(5)907–912, discussion 912 – 14
   PubMed Web of Science ®Google Scholar
• Soo T M, Bernstein M, Provias J, Tasker R, Lozano A, Guha A. Failed stereotactic biopsy in a series of 518 cases. Stereotact Funct Neurosurg 1995; 64(4)183–196
   PubMedGoogle Scholar
• Fritsch M J, Leber M J, Gossett L, Lulu B A, Hamilton A J. Stereotactic biopsy of intracranial brain lesions. High diagnostic yield without increased complications: 65 consecutive biopsies with early postoperative CT scans. Stereotact Funct Neurosurg 1998; 71(1)36–42
   PubMedGoogle Scholar
• Bernstein M, Parrent A G. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 1994; 81(2)165–168
   PubMed Web of Science ®Google Scholar
• DOH. Hospital Episode Statistics, Available at: http://www.hesonline.nhs.uk/Ease/servlet/DynamicPageBuild?siteID=1802&categoryID=192&catName=Free%20data (accessed: 16 October 2005)
   Google Scholar
• Kleihues P, Cavenee W K. Pathology and genetics: tumours of the nervous system, , et al. International Agency for Research on Cancer, 2000, Lyon
   Google Scholar
• Kreth F W, Warnke P C, Scheremet R, Ostertag C B. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993; 78(5)762–766
   PubMedGoogle Scholar
• Devaux B C, O'Fallon J R, Kelly P J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993; 78(5)767–775
   PubMedGoogle Scholar
• Lacroix M, Abi-Said D, Fourney D R, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2)190–198
   PubMed Web of Science ®Google Scholar
• Polin R S, Marko N F, Ammerman M D, et al. Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg 2005; 102(2)276–283
   PubMed Web of Science ®Google Scholar
• Laws E R, Parney I F, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99(3)467–473
   PubMed Web of Science ®Google Scholar
• Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359(9311)1011–1018
   PubMed Web of Science ®Google Scholar
• Fine H A, Dear K B, Loeffler J S, Black P M, Canellos G P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71(8)2585–2597
   PubMed Web of Science ®Google Scholar
• Burger P C, Vogel F S, Green S B, Strike T A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985; 56(5)1106–1111
   PubMedGoogle Scholar
• Walker M D, Alexander E, Jr, Hunt W E, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49(3)333–343
   PubMed Web of Science ®Google Scholar
• DeAngelis L M. Brain tumors. N Engl J Med 2001; 344(2)114–123
   PubMed Web of Science ®Google Scholar
• Zweig M H, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39(4)561–577
   PubMed Web of Science ®Google Scholar
• Fukuda M E, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005; 65(12)5190–5194
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng S, Yu J K, Zhang J M, Chen Z. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B 2005; 6(1)4–10
   PubMedGoogle Scholar
• Zheng P P, Hop W C, Sillevis Smitt P A, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res 2005; 11(12)4388–4392
   PubMedGoogle Scholar
• Papadopoulos M C, Abel P M, Agranoff D, et al. A novel and accurate diagnostic test for human African trypanosomiasis. Lancet 2004; 363(9418)1358–1363
   PubMed Web of Science ®Google Scholar
• Ardekani A M, Liotta L A, Petricoin E F, III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002; 2(4)312–320
   PubMedGoogle Scholar
• Tanwar M K, Gilbert M R, Holland E C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62(15)4364–4368
   PubMed Web of Science ®Google Scholar
• Papadopoulos M C, Saadoun S, Davies D C, Bell B A. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001; 15(2)101–108
   PubMed Web of Science ®Google Scholar
• Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005; 4(4)1213–1222
   PubMed Web of Science ®Google Scholar
• Thulasiraman V, Lin S, Gheorghiu L, et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005; 26(18)3561–3571
   PubMed Web of Science ®Google Scholar
• Fung E T, Yip T T, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005; 115(5)783–789
   PubMed Web of Science ®Google Scholar
• Khan-Farooqi H R, Prins R M, Liau L M. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res 2005; 27(7)692–702
   PubMed Web of Science ®Google Scholar
• Prins R M, Liau L M. Cellular immunity and immunotherapy of brain tumors. Front Biosci 2004; 9: 3124–3136
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92(25)11810–11813
   PubMed Web of Science ®Google Scholar
• Rege T A, Fears C Y, Gladson C L. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro-oncol 2005; 7(2)106–121
   PubMedGoogle Scholar
• Gonzalez-Martin A, Munoz-Espin D, Alonso A M, Izquierdo M. Parent phenotype and age dependence, on rat glioma tumor rejection. J Neurooncol 2004; 70(1)29–34
   PubMedGoogle Scholar
• Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353(12)1224–1235
   PubMed Web of Science ®Google Scholar
• Ribom D, Westman-Brinkmalm A, Smits A, Davidsson P. Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol 2003; 24(2)94–99
   PubMed Web of Science ®Google Scholar
• Ribom D, Larsson A, Pietras K, Smits A. Growth factor analysis of low-grade glioma CSF: PDGF and VEGF are not detectable. Neurol Sci 2003; 24(2)70–73
   PubMedGoogle Scholar
• Romeo M J, Espina V, Lowenthal M, Espina B H, Petricoin E F, III, Liotta L A. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005; 2(1)57–70
   PubMed Web of Science ®Google Scholar
• Pomeroy S L, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415(6870)436–442
   PubMed Web of Science ®Google Scholar
• Schwartz S A, Weil R J, Thompson R C, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005; 65(17)7674–7681
   PubMed Web of Science ®Google Scholar
• Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005; 37(Suppl)S38–45
   PubMed Web of Science ®Google Scholar
• Mischel P S, Cloughesy T F, Nelson S F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004; 5(10)782–792
   PubMed Web of Science ®Google Scholar
• Rhodes D R, Chinnaiyan A M. Integrative analysis of the cancer transcriptome. Nat Genet 2005; 37(Suppl)S31–37
   PubMedGoogle Scholar
• Rhodes D R, Kalyana-Sundaram S, Mahavisno V, Barrette T R, Ghosh D, Chinnaiyan A M. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005; 37(6)579–583
   PubMedGoogle Scholar
• Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005; 102(16)5814–5819
   PubMed Web of Science ®Google Scholar
• Sallinen S L, Sallinen P K, Haapasalo H K, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000; 60(23)6617–6622
   PubMed Web of Science ®Google Scholar
• Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005; 64(1)10–14
   PubMed Web of Science ®Google Scholar
• Huang H, Okamoto Y, Yokoo H, et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 2004; 23(35)6012–6022
   PubMedGoogle Scholar
• Neben K, Korshunov A, Benner A, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64(9)3103–3111
   PubMed Web of Science ®Google Scholar
• Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163(5)1721–1727
   PubMed Web of Science ®Google Scholar
• Scherf U, Ross D T, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24(3)236–244
   PubMed Web of Science ®Google Scholar
• Staunton J E, Slonim D K, Coller H A, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001; 98(19)10787–10792
   PubMedGoogle Scholar
• Butte A J, Tamayo P, Slonim D, Golub T R, Kohane I S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci USA 2000; 97(22)12182–12186
   PubMed Web of Science ®Google Scholar
• Vercauteren F G, Bergeron J J, Vandesande F, Arckens L, Quirion R. Proteomic approaches in brain research and neuropharmacology. Eur J Pharmacol 2004; 500(1 – 3)385–398
   PubMedGoogle Scholar
• Lueking A, Cahill D J, Mullner S. Protein biochips: a new and versatile platform technology for molecular medicine. Drug Discov Today 2005; 10(11)789–794
   PubMedGoogle Scholar
• Angenendt P. Progress in protein and antibody microarray technology. Drug Discov Today 2005; 10(7)503–511
   PubMedGoogle Scholar
• Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64(7)2496–2501
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309(3)558–566
   PubMed Web of Science ®Google Scholar
• Zhang R, Tremblay T L, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003; 42(2)194–208
   PubMedGoogle Scholar
• Villanueva J, Yanes O, Querol E, Serrano L, Aviles F X. Identification of protein ligands in complex biological samples using intensity-fading MALDI-TOF mass spectrometry. Anal Chem 2003; 75(14)3385–3395
   PubMedGoogle Scholar
• Zheng P P, Luider T M, Pieters R, et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003; 62(8)855–862
   PubMed Web of Science ®Google Scholar
• Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994; 10(4)191–247
   PubMedGoogle Scholar
• Howe F A, Barton S J, Cudlip S A, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49(2)223–232
   PubMedGoogle Scholar
• Burtscher I M, Skagerberg G, Geijer B, Englund E, Stahlberg F, Holtas S. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000; 21(1)84–93
   PubMedGoogle Scholar
• Tzika A A, Zarifi M K, Goumnerova L, et al. Neuroimaging in pediatric brain tumors: Gd-DTPA-enhanced, hemodynamic, and diffusion MR imaging compared with MR spectroscopic imaging. AJNR Am J Neuroradiol 2002; 23(2)322–333
   PubMedGoogle Scholar
• Wald L L, Nelson S J, Day M R, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997; 87(4)525–534
   PubMedGoogle Scholar
• Nelson S J, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002; 16(4)464–476
   PubMedGoogle Scholar
• Law M, Cha S, Knopp E A, Johnson G, Arnett J, Litt A W. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222(3)715–721
   PubMedGoogle Scholar
• Graves E E, Nelson S J, Vigneron D B, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001; 22(4)613–624
   PubMedGoogle Scholar
• Dowling C, Bollen A W, Noworolski S M, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001; 22(4)604–612
   PubMed Web of Science ®Google Scholar
• Martin A J, Liu H, Hall W A, Truwit C L. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR Am J Neuroradiol 2001; 22(5)959–968
   PubMedGoogle Scholar
• Valafar F. Pattern recognition techniques in microarray data analysis: a survey. Ann N Y Acad Sci 2002; 980: 41–64
   PubMed Web of Science ®Google Scholar
• Poon T C, Hui A Y, Chan H L, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005; 51(2)328–335
   PubMedGoogle Scholar
• Petricoin E F, Ardekani A M, Hitt B A, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359(9306)572–577
   PubMed Web of Science ®Google Scholar